论文部分内容阅读
目的研究DDP+CPT-11及DDP+VP-16两种方案分别治疗小细胞肺癌的临床疗效、不良反应和生存质量。方法PI组30例患者,DDP60mg/m2静脉滴注,d1;依利替康60mg/m2,静脉滴注,d1、8、15。PE组20例患者,DDP60mg/m2,静脉滴注,d1;Vp-16100mg/m2静脉滴注,d1～5。两种方案均为28d为1个周期,连续治疗2～3个周期。结果PI组1年生存率为58.2%,2年生存率为18.7%;PE组1年生存率为37.5%,2年生存率为6.3%。结论PI组临床疗效、生存质量优于PE组,是临床较好的治疗方案。
Objective To study the clinical efficacy, side effects and quality of life of two kinds of regimens of DDP + CPT-11 and DDP + VP-16 in the treatment of small cell lung cancer. Methods PI patients 30 patients, DDP60mg / m2 intravenous drip, d1; irinotecan 60mg / m2, intravenous drip, d1,8,15. PE group 20 patients, DDP60mg / m2, intravenous drip, d1; Vp-16100mg / m2 intravenous drip, d1 ~ 5. Two programs are 28d for a cycle, continuous treatment of 2 to 3 cycles. Results The 1-year survival rate was 58.2% in PI group and 18.7% in 2-year survival rate. The 1-year survival rate was 37.5% in PE group and 6.3% in 2-year survival rate. Conclusion The clinical efficacy and quality of life of PI group are better than that of PE group, which is a better clinical treatment plan.